Vial Has Added NEXT Oncology, a Global Network of Phase I Cancer Research Centers, to their Preferred Site Network

San Francisco, CA. November 21, 2022 — Vial has added NEXT Oncology to their Preferred Site Network. Founded by renowned oncologist Dr. Anthony W. Tolcher, NEXT Oncology is a global network of Phase I cancer research clinics dedicated to providing patients access to the latest treatments for advanced cancers. Headquartered in San Antonio, Texas, NEXT Oncology has expanded locations across the United States and Spain.

“Dr. Tolcher has devoted over 30 years to developing new anticancer agents for patients whose cancer therapies have ceased to benefit them. We are thrilled NEXT Oncology has joined our Preferred Site Network and look forward to working with Dr. Tolcher and his clinical network to advance oncology research,” said Wendy Pinson, Director of Clinical Operations at Vial.

Dr. Tolcher is a board-certified medical oncologist and an internationally renowned key opinion leader in the field of oncology. He specialized in internal medicine and medical oncology in residency programs at the University of Toronto and the University of British Columbia, where he received his MD. Dr. Tolcher is a highly experienced researcher in early-stage clinical trials that target cancer therapies via innovative treatments, including antibody drug conjugates (ADCs). His vision for NEXT Oncology is to continue the global expansion of NEXT clinics to bring life-saving therapies to people around the world.

On the partnership, Dr. Tolcher comments, “My mission and the mission of the company has always been to support and accelerate innovation in oncology in order to improve patient outcomes. By investing in technologies that can accelerate innovation, we are able to contribute to this mission. The approach and the technologies Vial is driving forward are exciting and could meaningfully contribute to making trials more efficient.”

The Vial Preferred Site Network connects dedicated sites to leading sponsors for more streamlined trials, managed by the Vial CRO, that bring new therapies to market faster. Investigators in the Vial Preferred Site Network have undergone a comprehensive selection process, ensuring every site is equipped for seamless trial execution via technology-enabled methods from site startup to database lock. Investigators that join Vial’s Preferred Site Network gain exclusive trial access and the opportunity to grow their research business.

Vial is excited to leverage proXimity, an innovative cloud-based software platform, to automate the transfer of clinical trial data from their electronic medical record (EMR) to sponsors’ electronic data capture (EDC) systems. Automating this process will accelerate clinical trial performance, getting new therapies to market quicker for patients with cancer.

About NEXT Oncology: NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provides NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.

About Vial: Vial is a tech-enabled, next-generation CRO that promises faster, more efficient execution of clinical trials for less. The Vial Preferred Site Network offers a robust investigator community across a wide range of therapeutic areas (DermatologyOphthalmologyOncologyGastroenterology, Neurology, and Cardiology), connecting dedicated sites to leading sponsors for more streamlined trials that bring new therapies to market faster. Vial is a San Francisco, California-based company with over 125 employees.

Contact Us

By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.